Core Viewpoint - The company is focusing on the application of iodides in the perovskite field and has initiated technical research and product development in this area, with ongoing projects but no product sales yet [1] Company Overview - The company, Boyuan Co., Ltd. (301617), has a current iodide production capacity of 4,100 tons per year [1] - There is an additional project in the trial production phase with a capacity of 4,000 tons per year [1]

Core Viewpoint - The company is focusing on the application of iodides in the perovskite field and has initiated technical research and product development in this area, with ongoing projects but no product sales yet [1] Group 1 - The company has an existing iodide production capacity of 4,100 tons per year [1] - There is an additional project in the trial production stage with a capacity of 4,000 tons per year [1]

Core Insights - The company has recognized the application of iodides in the perovskite battery sector and is actively conducting technical research and product development in this area [1] Group 1 - The company is currently advancing its research and development projects related to iodides in perovskite batteries [1] - No products have been commercialized or sold yet as the R&D projects are still in progress [1]

Group 1: Company Overview - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., has an existing production capacity of 4,100 tons/year for iodide products, with a trial production project of 4,000 tons/year [2] - The main inorganic iodides include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, while the organic iodides include trimethyl iodide and iodomethane [2] Group 2: Applications and Market Distribution - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, widely used in various product formulations [2] - The major applications of iodine include X-ray contrast agents, biocides, preservatives, pharmaceutical intermediates, LCD and LED screen polarizers, chemicals, organic compounds, and pigments [2] - According to SQM's 2024 annual report, the core application areas of iodine account for approximately 63% of global consumption, with significant production concentrated in Chile, Japan, and the USA, which together account for 88% of global sales [3] Group 3: Financial Performance - The company's net profit decreased year-on-year in the first nine months of 2025, primarily due to rising upstream material prices, which increased product cost pressures [3] Group 4: Production Processes and Innovations - The production of lithium iodide utilizes raw materials such as hydriodic acid, lithium carbonate, formic acid, activated carbon, and lithium hydroxide, involving processes like neutralization, vacuum concentration, cooling crystallization, filtration, and vacuum drying [3] - The company is conducting research and product development on the application of iodides in perovskite batteries, with related R&D projects currently in progress, but no products have been sold as of the report date [3]

Group 1: Company Overview - The company is Shandong Boyuan Pharmaceutical Chemical Co., Ltd., with stock code 301617 and abbreviation Boyuan Co., Ltd. [1] Group 2: Production Capacity - The current production capacity for iodide products is 4,100 tons/year, with trial production at 4,000 tons/year [2] - Inorganic iodides include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide; organic iodides include trimethyl iodide and iodomethane [2] Group 3: Applications and Market Distribution - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, with applications in X-ray contrast agents, disinfectants, pharmaceuticals, LCD and LED screens, and more [2] - The three core application areas—medical manufacturing and LCD panel manufacturing—account for approximately 63% of global iodine consumption [3] - Major iodine production is concentrated in Chile, Japan, and the USA, which together account for 88% of global sales [3] Group 4: Market Trends - The procurement price of iodine has shown an upward trend in recent years, with prices rising from 2020 to 2023 and stabilizing at relatively high levels without significant declines [3] Group 5: Financial Status - The company currently has a strong financial position, with healthy cash flow that adequately covers daily operations and project investments, indicating no financial pressure [3]

Core Viewpoint - The company is actively researching and developing products related to the application of iodides in the perovskite field, with ongoing projects but no products available for sale yet [1]. Group 1 - The company has acknowledged the potential of iodides in the perovskite sector [1]. - Technical research and product development efforts are currently underway [1]. - The related R&D projects are in progress but have not yet resulted in product sales [1].

Group 1 - The company is exploring the application of iodides in the perovskite field and has initiated technical research and product development in this area [2] - Current research and development projects related to iodides and perovskites are in progress, but no products have been commercialized yet [2]

Group 1: Company Overview - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., focuses on fine chemicals, with iodides being the primary revenue contributor [2]. - The current production capacity for iodide products is 4,100 tons/year, with an additional 4,000 tons/year in trial production [2]. Group 2: Product Details - The main categories of fine chemicals include iodides, luminescent materials, hexamethyldisilazane, and precious metal catalysts, with iodides leading in revenue [2]. - The inorganic iodides include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, while organic iodides consist of trimethyl iodide and iodomethane [2]. Group 3: Market Outlook - The market for inorganic iodides is expected to grow due to increasing demand in the pharmaceutical sector, driven by rising healthcare spending and aging populations [3]. - The demand for iodinated contrast agents in medical imaging (CT and MRI) is projected to rise, contributing to the expansion of the domestic contrast agent market [3]. - In the electronics manufacturing sector, the shift of global panel production to China is increasing the domestic market share of polarizer manufacturers, with iodinated polarizers holding an 80%-90% market share [3]. Group 4: Shareholder Information - A total of 19,630,000 shares will be released from lock-up on December 11, 2025, with no current plans for shareholder reduction reported [3]. - The company will disclose any future reduction plans in accordance with legal requirements [3]. Group 5: Raw Material Sourcing - The company sources iodine through a dual-channel model of "resource recycling and recovery + import supplementation" [5].

Group 1: Company Overview - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., has a stock code of 301617 and is referred to as Boyuan Co. [1] Group 2: Investor Relations Activity - The investor relations activity involved a specific audience survey and included participants from various financial institutions such as Nuode Fund, Changjiang Securities, and others [2] - The meeting took place on October 31, 2025, in the Boyuan Co. conference room [2] Group 3: Product Capacity and Applications - The company has an existing production capacity of 4,100 tons/year for iodide products, which include inorganic iodides like potassium iodide and sodium iodide, as well as organic iodides such as trimethyl iodide [2][3] - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, with applications in X-ray contrast agents, disinfectants, and LCD/LED screen polarizers [3] Group 4: Strategic Partnerships - Boyuan Co. signed a strategic cooperation framework agreement with Dongsheng Technology in October 2025, focusing on resource integration and technological innovation to enhance competitiveness in the solid-state battery materials industry [2] Group 5: Global Iodine Market Insights - According to SQM's 2024 annual report, the downstream application structure of iodine shows that X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing account for approximately 63% of global consumption [3] - The global iodine production is concentrated in Chile, Japan, and the USA, which together account for 88% of total sales, with Chilean companies alone contributing 60% of global iodine sales [3]

Core Viewpoint - The company is expanding its business into hexamethyldisilazane products based on the common needs of its existing pharmaceutical clients and its advantages in resource utilization and technology [1] Group 1: Business Expansion - The company has identified a demand from its existing pharmaceutical clients for hexamethyldisilazane products, leading to its business expansion in this area [1] - The expansion into hexamethyldisilazane requires minimal additional investment and offers cost advantages in raw material acquisition [1] Group 2: Resource Utilization - The company has established a collaborative foundation in resource utilization, including operational qualifications, incineration facilities, shared equipment, production sites, practical experience, and a professional team [1] - The company is leveraging its strengths in waste recovery to extend its operations from organic solvent recovery to the recycling of siloxanes [1] Group 3: Market Positioning - Both iodides and hexamethyldisilazane are functional additives used in the pharmaceutical chemical process, sharing similar application scenarios and functional characteristics [1] - The company is strategically positioning itself in the market by utilizing its existing iodide products as a basis for the new hexamethyldisilazane product line, aligning with market demand and competitive landscape [1]